Ask Warren

Orientbio

002630 · KOSPI · ₩002630 · 오리엔트바이오

₩1,190▼ ₩39 (3.17%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Revenue₩6.6B₩6.2B₩8.6B₩6.9B₩7.7B₩4.9B₩9B₩6.7B
Cost of sales₩4.6B₩2.2B₩7.8B₩5.2B₩6.9B₩322M₩8.1B₩5B
Gross profit₩2B₩4B₩814M₩1.7B₩746M₩4.6B₩879M₩1.7B
Operating income₩50M₩796M−₩1.6B−₩680M−₩1.6B₩1.8B−₩1.7B−₩691M
Net income₩4.8B−₩9.1B−₩1.9B−₩151M−₩2B₩22B−₩1.2B−₩1.1B
Net income to shareholders₩4.8B−₩9.1B−₩1.9B−₩151M−₩2B₩22B−₩1.2B−₩1.1B

Balance sheet

Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Total assets₩83B₩85B₩80B₩82B₩83B₩97B₩89B₩91B
Current assets₩50B₩47B₩46B₩45B₩46B₩59B₩48B₩50B
Cash and equivalents₩11B₩6.5B₩7.5B₩5.5B₩4.5B₩6.1B₩6.3B₩5.7B
Total liabilities₩11B₩13B₩13B₩13B₩13B₩12B₩12B₩13B
Current liabilities₩3.6B₩4.2B₩4B₩3.8B₩4.6B₩4.2B₩4.3B₩5B
Borrowings₩105M₩105M₩105M₩105M₩105M₩105M₩105M₩105M
Total equity₩72B₩72B₩68B₩70B₩70B₩85B₩77B₩78B
Shareholders' equity₩72B₩72B₩68B₩70B₩70B₩85B₩77B₩78B

Cash flow

Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Cash from operations₩4B−₩617M₩1.8B₩99M−₩499M₩3B−₩593M₩1.6B
Capital spending₩95M−₩3.3B−₩2.6B₩109M₩947M₩5.6B−₩8B₩1.5B
Free cash flow₩3.9B−₩3.9B−₩796M−₩10M−₩1.4B−₩2.6B−₩8.5B₩179M

Consolidated where available. Amounts in won.

Also known as: Orientbio / 오리엔트바이오 / 002630 / KRX:002630

Source: KRX statistical information